These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37282628)

  • 1. Anxiety exacerbation in a patient with chronic myeloid leukemia receiving dasatinib and venlafaxine.
    Bell C; Signorelli J; Hobbs G
    J Oncol Pharm Pract; 2023 Oct; 29(7):1762-1765. PubMed ID: 37282628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dasatinib-associated reversible demyelinating peripheral polyneuropathy in a case of chronic myeloid leukemia.
    Ishida T; Akagawa N; Miyata T; Tominaga N; Iizuka T; Higashihara M; Suzuki T; Miyazaki K
    Int J Hematol; 2018 Mar; 107(3):373-377. PubMed ID: 29027647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained molecular response following a failed attempt of tyrosine kinase inhibitor discontinuation & the effects on growth in a child with chronic myeloid leukemia: not always a short story.
    Triche L; Yarbrough A; Roth M; Ying A; Wells R
    Pediatr Hematol Oncol; 2020 Aug; 37(5):375-379. PubMed ID: 32347770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
    Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.
    Claudiani S; Apperley JF; Szydlo R; Khan A; Nesr G; Hayden C; J Innes A; Dominy K; Foskett P; Foroni L; Khorashad J; Milojkovic D
    Br J Haematol; 2021 Apr; 193(2):346-355. PubMed ID: 33368155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unexpected pancytopenia: Dasatinib induced aplastic anemia in chronic myeloid leukemia.
    Feld J; Steinberg A; El Jamal SM; Shapira I
    J Oncol Pharm Pract; 2022 Jan; 28(1):232-236. PubMed ID: 34152210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia.
    Sogawa R; Kimura S; Yakabe R; Mizokami Y; Tasaki M; Sueoka-Aragane N; Narisawa Y; Kimura S
    Int J Clin Oncol; 2018 Oct; 23(5):974-979. PubMed ID: 29651584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.
    Trivedi D; Landsman-Blumberg P; Darkow T; Smith D; McMorrow D; Mullins CD
    J Manag Care Spec Pharm; 2014 Oct; 20(10):1006-15. PubMed ID: 25278323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Facial Edema Associated with Dasatinib: Case Report with Successful Treatment.
    Nyckowski T; Ambur A; Vinokurov A; Nathoo R
    J Oncol Pharm Pract; 2022 Jul; 28(5):1211-1213. PubMed ID: 35068252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevalence of Adverse Effects of Tyrosine Kinase Inhibitors Used in Management of Chronic Myeloid Leukemia at Sidi Bel-Abbès University Hospital Center].
    Matmour D; Si-Ali N; Benmehimda NC; Beloufa S; Belfrak F; Mahi E; Merad Y; Toumi H; Benlazar M
    Ann Pharm Fr; 2022 Nov; 80(6):932-942. PubMed ID: 35469781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.
    Hirji I; Gupta S; Goren A; Chirovsky DR; Moadel AB; Olavarria E; Victor TW; Davis CC
    Health Qual Life Outcomes; 2013 Oct; 11():167. PubMed ID: 24099272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful dasatinib therapy in newly diagnosed chronic myeloid leukemia in the setting of short bowel syndrome.
    Freydman J; Staron A; Hughes D; Sloan JM
    J Oncol Pharm Pract; 2023 Sep; 29(6):1489-1493. PubMed ID: 37157792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group.
    Yamaguchi H; Takezako N; Ohashi K; Oba K; Kumagai T; Kozai Y; Wakita H; Yamamoto K; Fujita A; Igarashi T; Yoshida C; Ohyashiki K; Okamoto S; Sakamoto J; Sakamaki H; Inokuchi K
    Int J Hematol; 2020 Mar; 111(3):401-408. PubMed ID: 31894533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
    Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
    Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
    Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
    Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
    Naqvi K; Jabbour E; Skinner J; Anderson K; Dellasala S; Yilmaz M; Ferrajoli A; Bose P; Thompson P; Alvarado Y; Jain N; Takahashi K; Burger J; Estrov Z; Borthakur G; Pemmaraju N; Paul S; Cortes J; Kantarjian HM
    Cancer; 2020 Jan; 126(1):67-75. PubMed ID: 31553487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Results of following up patients with chronic myeloid leukemia and a deep molecular response without tyrosine kinase inhibitor therapy].
    Turkina AG; Chelysheva EY; Shuvaev VA; Gusarova GA; Bykova AV; Shukhov OA; Petrova AN; Vakhrusheva MV; Goryacheva SR; Kolosova LY; Krasikova PS; Fominykh MS; Martynkevich IS; Abdullaev AO; Sudarikov AB; Savchenko VG
    Ter Arkh; 2017; 89(12):86-96. PubMed ID: 29411766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of chronic myeloid leukemia in 2023 - common ground and common sense.
    Senapati J; Sasaki K; Issa GC; Lipton JH; Radich JP; Jabbour E; Kantarjian HM
    Blood Cancer J; 2023 Apr; 13(1):58. PubMed ID: 37088793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Irvine E; Williams C
    Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.